Home - Anthos Therapeutics
WEBMore than 1 in 4 people worldwide die from arterial thromboembolic events (ischemic heart disease or stroke). Anthos Therapeutics is highly committed to addressing this and other areas of high unmet need. Stroke Prevention in Patients with Atrial Fibrillation.
Anthos Therapeutics Announces that Abelacimab has Received …
WEBJul 11, 2022 · Abelacimab is a novel, highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition. Abelacimab targets the active...
Anthos Therapeutics Announces that Abelacimab Has Received …
WEBAug 15, 2024 · Anthos Therapeutics Announces that Abelacimab Has Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation. CAMBRIDGE, Mass., Sept. 8, 2022 – Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases ...
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in …
WEBJan 3, 2023 · Anthos Therapeutics FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation
Anthos Therapeutics Announces that Abelacimab Has Received …
WEBSep 8, 2022 · Abelacimab is a dual-acting, once-monthly, fully human monoclonal antibody targeting both Factor XI and Factor XIa with high affinity and selectivity. Story continues. This is the second Fast ...
Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor ...
WEBNov 12, 2023 · Anthos Therapeutics has initiated an extension study to enable patients to transition from rivaroxaban to abelacimab to benefit from the improved bleeding profile. This press release features...
Anthos blood thinner bests Xarelto on safety in mid-stage study
WEBNov 13, 2023 · An experimental blood thinner dramatically cut the risk of major bleeding versus the widely used drug Xarelto in a mid-stage study of nearly 1,300 people with atrial fibrillation, results presented Sunday at the American Heart Association’s meeting showed.
Anthos Therapeutics' novel Factor XI inhibitor abelacimab …
WEBCAMBRIDGE, Mass., July 19, 2021 /PRNewswire/ -- Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced...
Regulatory Authorities in China and Japan Approve Clinical
WEBCAMBRIDGE, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today...
Abelacimab: First Factor XI Inhibitor to Enroll Patients in a Phase 3 ...
WEBAug 15, 2024 · In the ASTER trial, Anthos’ novel dual-acting Factor XI monoclonal antibody, abelacimab, is being compared to apixaban, the leading Factor Xa inhibitor, to assess their effects on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE.